Darzalex 1 800 1 800 mg Solution for injection.
PDF Leaflet Revision Date: 12 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and AL amyloidosis.
Dosage (summary)
1800 mg subcutaneously; varies by regimen.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding.
Key Drug Interactions
- Live vaccines
- Corticosteroids
Contraindications
- Hypersensitivity to daratumumab or excipients
Common side effects
- Infusion-related reactions
- Fatigue
- Nausea
- Diarrhoea
- Neutropenia
Counselling Points
- Pre-medicate to reduce IRRs
- Monitor for signs of infection
- Avoid live vaccines
Serious warnings
- Serious infusion-related reactions
- Hepatitis B reactivation
Important Disclaimer
The Darzalex 1 800 1 800 mg Solution for injection. professional information leaflet below is the property of Janssen Pharmaceutica (Pty) Ltd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
